[
  {
    "ts": null,
    "headline": "Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know",
    "summary": "In the latest trading session, Abbott (ABT) closed at $113.29, marking a +0.59% move from the previous day.",
    "url": "https://finnhub.io/api/news?id=0b4cc661576d6ce60a29df91430dc2958c1bfb63fc81564625edda183ad916cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734475814,
      "headline": "Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know",
      "id": 132034101,
      "image": "https://media.zenfs.com/en/zacks.com/48ad4265c55e3ba7a1fb9148d6e717d9",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "In the latest trading session, Abbott (ABT) closed at $113.29, marking a +0.59% move from the previous day.",
      "url": "https://finnhub.io/api/news?id=0b4cc661576d6ce60a29df91430dc2958c1bfb63fc81564625edda183ad916cc"
    }
  },
  {
    "ts": null,
    "headline": "Abbott's FreeStyle Libre® 2 Now Reimbursed for Children and Adults Living with Diabetes in Alberta",
    "summary": "Abbott (NYSE: ABT) today announced that the Government of Alberta has added Abbott's FreeStyle Libre 2* flash glucose monitoring system to the Alberta Drug Benefit List.",
    "url": "https://finnhub.io/api/news?id=1e7a32587ad9c120de5f428dd99fd76c13679c099fa91aa7f3e287329546f72d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734469380,
      "headline": "Abbott's FreeStyle Libre® 2 Now Reimbursed for Children and Adults Living with Diabetes in Alberta",
      "id": 132034102,
      "image": "https://media.zenfs.com/en/cnwgroup.com/6d33c2ff31047ed885c3c278cbad68e3",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced that the Government of Alberta has added Abbott's FreeStyle Libre 2* flash glucose monitoring system to the Alberta Drug Benefit List.",
      "url": "https://finnhub.io/api/news?id=1e7a32587ad9c120de5f428dd99fd76c13679c099fa91aa7f3e287329546f72d"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
    "summary": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
    "url": "https://finnhub.io/api/news?id=4521bcee01fcb767a5447d537f8800ca8de90950051dcbac56f8924370b6700c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734453360,
      "headline": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
      "id": 132065765,
      "image": "",
      "related": "ABT",
      "source": "MarketWatch",
      "summary": "Abbott Laboratories stock underperforms Tuesday when compared to competitors despite daily gains",
      "url": "https://finnhub.io/api/news?id=4521bcee01fcb767a5447d537f8800ca8de90950051dcbac56f8924370b6700c"
    }
  },
  {
    "ts": null,
    "headline": "Are Abbott Laboratories' (NYSE:ABT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?",
    "summary": "It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has...",
    "url": "https://finnhub.io/api/news?id=8216050b48359433695f9c8a727db17d4f19da4de170ffe6cb2922ddd5986cd2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436836,
      "headline": "Are Abbott Laboratories' (NYSE:ABT) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?",
      "id": 132026998,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/983f2bdfe32b19227b1d118c45bf4f09",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "It is hard to get excited after looking at Abbott Laboratories' (NYSE:ABT) recent performance, when its stock has...",
      "url": "https://finnhub.io/api/news?id=8216050b48359433695f9c8a727db17d4f19da4de170ffe6cb2922ddd5986cd2"
    }
  },
  {
    "ts": null,
    "headline": "Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart",
    "summary": "Abbott (NYSE: ABT) today announced the successful completion of the world's first in-human leadless left bundle branch area pacing (LBBAP) procedures using the company's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system, as part of a feasibility study. These procedures mark the first time a leadless pacemaker has been implanted into the left bundle branch area, a key part of the heart's electrical conduction system, designed to mimic the heart's natural beat, offeri",
    "url": "https://finnhub.io/api/news?id=f268c7f5653e790de5147f5a5145fec5496d01715b4bced70c7aae4a7a91ed71",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734436800,
      "headline": "Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart",
      "id": 132026999,
      "image": "https://media.zenfs.com/en/prnewswire.com/6c2e4620beb5c9ef78485cf333ab4399",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (NYSE: ABT) today announced the successful completion of the world's first in-human leadless left bundle branch area pacing (LBBAP) procedures using the company's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system, as part of a feasibility study. These procedures mark the first time a leadless pacemaker has been implanted into the left bundle branch area, a key part of the heart's electrical conduction system, designed to mimic the heart's natural beat, offeri",
      "url": "https://finnhub.io/api/news?id=f268c7f5653e790de5147f5a5145fec5496d01715b4bced70c7aae4a7a91ed71"
    }
  },
  {
    "ts": null,
    "headline": "Mairs & Power Balanced Fund Q3 2024 Commentary",
    "summary": "The Mairs & Power Balanced Fund finished the first nine months of 2024 up 11.02%. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=8eddadab94cf3228ebe784eeed3079bc85159393428d030a121432591eb155b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734417300,
      "headline": "Mairs & Power Balanced Fund Q3 2024 Commentary",
      "id": 132023135,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/955408614/image_955408614.jpg?io=getty-c-w1536",
      "related": "ABT",
      "source": "SeekingAlpha",
      "summary": "The Mairs & Power Balanced Fund finished the first nine months of 2024 up 11.02%. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=8eddadab94cf3228ebe784eeed3079bc85159393428d030a121432591eb155b2"
    }
  }
]